Currently Enrolling Trials
Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy (protocol AB)
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk (protocol W)
A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability.
The Correlation of Checkup Vision Assessment System to Standard In Office Visual Assessment (CLEAR)
Active Clinical Trials (Closed for enrollment)
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration (Alcon HAWK trial)
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (Allergan CEDAR)
A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Soluon, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneraon (OHR 1601)
A randomized, multi-center, single masked, sham controlled, proof-of –concept study of intravitreal CLG561 as a monotherapy or in combination with LFG316 in patents with geographic atrophy (Alcon CLG561)
A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated With Proliferative Diabetic Retinopathy
Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time. (Protocol AA)
Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity (Protocol V)
Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.